Highlights
IIA supported (ever)1 patent
About
Implantable Bioreactor for Treating Type 1 Diabetes
Beta-O2 Technologies is a biomedical company developing a proprietary implantable bioreactor, the Air, for the treatment of patients with type 1 diabetes. The Air is a small medical device that is implanted in a minimally invasive procedure. The device, which contains islets of Langerhans, is intended to free patients from insulin injections and continuous monitoring of glucose levels. The device also reduces the risk of hypoglycemic episodes and other complications of the condition. Because the Air device contains living cells, the patient needs to refill the air in the device using a replenishing device, which includes a dedicated injector.
Identity
| Name | Beta-O2 Technologies |
|---|---|
| Slug | beta-o2 |
| Type / kind | startup |
| Crunchbase ID | beta-o2-technologies |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL6q6LoKDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Aug 2025 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Rosh Haayin |
| HQ address | Amal Street 11, Rosh Haayin, Israel |
Web & social
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyBiomaterials & Tissue EngineeringMedical DevicesMedical Treatment & Therapeutics
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesHealthcarePatientsProviders
Business models
B2B
Tags
biotechnologyminimally-invasivediabetesmedical-devices
Funding
| Total raised | $8.2M |
|---|---|
| Current stage | Mature |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}